OBJECTIVE:To provide reference for promoting the prior usage of essential medicines and scientifically selecting of antitumor medicines in the national and local drug reimbursement list. METHODS:Entering the Human Resources and Social Se-curity Bureau websites in 10 cities(Beijing,Shanghai,Guangzhou,Nanjing,Wuhan,Xi’an,Chengdu,Shenyang,Jinan and Gui-yang),drug reimbursement list was downloaded to statistically analyze the containing of antitumor medicines(including 24 essential medicines). RESULTS:In antitumor medicines,there were 5 cities with more than 100 varieties,of which Shanghai had 255 vari-eties,which was far more than other cities;the numbers of medicines in class A were near 30 in all the cities except Beijing(67 va-rieties),and the number of class B was highest in Shanghai and lowest in Beijing. All the drug reimbursement lists in 10 cities con-tained 24 antitumor essential medicines,however,the classification was different according to the dosage forms,among which, parts of formulations of cytarabine(injections),doxorubicin(injections),busulfan (often release oral dosage forms),fluorouracil (often release oral dosage forms,injections),cyclophosphamide(often release oral dosage forms,injections),methotrexate(often release oral dosage forms,injections)and cisplatin were classified as class A medicines in all cities;oxaliplatin(injections)and pa-clitaxel (injections) were classified as class B medicines;busulfan,fluorouracil,cyclophosphamide and methotrexate were classi-fied as class B in Shanghai only. CONCLUSIONS:There are some differences in the distribution of antitumor essential medicines in drug reimbursement list in each city,the varieties in developed cities are relatively more,and developing cities are less. It is sug-gested to consider the tumor epidemiology characteristics and economic situations,reasonably select antitumor essential medicines into drug reimbursement list and reasonably adjust the proportion of class A and B to ensure the basic medication and drugs’reim-bursement.%目的：为促进基本药物优先使用、国家及地方医保目录中抗肿瘤药物的科学遴选提供参考。方法：登陆我国北京、上海、广州、南京、武汉、西安、成都、沈阳、济南、贵阳10个城市的人力资源和社会保障局网站，下载各地医保目录，对其中的抗肿瘤药物（包括24种国家基本药物品种）的收载情况进行统计和分析。结果：医保目录收载的抗肿瘤药物品种数在100种以上的有5个城市，其中上海共有255种，远远多于其他城市；医保目录甲类药物除北京多达67种抗肿瘤药物外，其他城市数量均接近30种，而乙类药物上海最多，北京最少。24种抗肿瘤药物类基本药物在10个城市的医保目录中均有收载，但根据其剂型不同，在不同城市医保目录中归类有所差异，其中阿糖胞苷（注射剂）、阿霉素/多柔比星（注射剂）、白消安（口服常释剂型）、氟尿嘧啶（口服常释剂型、注射剂）、环磷酰胺（口服常释剂型、注射剂）、甲氨蝶呤（口服常释剂型、注射剂）、顺铂（注射剂）等16种药物的部分剂型在所有城市均归为甲类药物；奥沙利铂（注射剂）、紫杉醇（注射剂）在所有城市均归为乙类药物；白消安、氟尿嘧啶、环磷酰胺、甲氨蝶呤等的其他剂型仅在上海归为乙类药物。结论：各地区医保目录中抗肿瘤药物类基本药物分布有一定差异，发达城市品种数相对较多，欠发达城市品种数相对较少。建议各地参照当地肿瘤流行病学特点和经济状况，合理遴选抗肿瘤药物类基本药物纳入医保目录，并合理调整医保目录甲类与乙类药物比例，以保证基本用药和药品报销。
展开▼
